CDK4/6 inhibitors are currently only approved to treat ER+ breast cancers, but our data build on a growing body of evidence that suggest there may be clinical relevance in expanding the use of CDK4/6i in combination with DNA damaging or cytotoxic agents to treat TNBC and other cancer types. This evidence concerns the gene CDK4 and breast carcinoma.